Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pharmacokinetics, safety, and tolerability of intravenous brivaracetam in pediatric patients aged 1 month to under 16 years with epilep…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• BRIVARACETAM (brivaracetam)

Snippet

Sponsor: UCB Biopharma S.P.R.L. | Conditions: Epilepsy | Phase 2 | Status: COMPLETED | Results posted: 2021-11-26